Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
Top Cited Papers
- 1 June 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 371 (9630), 2093-2100
- https://doi.org/10.1016/s0140-6736(08)60919-8
Abstract
No abstract availableFunding Information
- GlaxoSmithKline
- Actelion Pharmaceuticals
- Pfizer
- Bayer
- United Therapeutics Corporation
This publication has 31 references indexed in Scilit:
- Results of European post-marketing surveillance of bosentan in pulmonary hypertensionEuropean Respiratory Journal, 2007
- Bosentan Therapy in Patients With Eisenmenger SyndromeCirculation, 2006
- Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist SitaxsentanJournal of the American College of Cardiology, 2006
- Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertensionEuropean Heart Journal, 2006
- Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2European Respiratory Journal, 2004
- Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover studyJournal of the American College of Cardiology, 2004
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionThe New England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Multiple Testings: Multiple Comparisons and Multiple EndpointsDrug Information Journal, 1998